Oral Nanomedicines for siRNA Delivery to Treat Inflammatory Bowel Disease

RNA interference (RNAi) therapies have significant potential for the treatment of inflammatory bowel diseases (IBD). Although administering small interfering RNA (siRNA) via an oral route is desirable, various hurdles including physicochemical, mucus, and cellular uptake barriers of the gastrointest...

Descripción completa

Detalles Bibliográficos
Autores principales: Shinn, Jongyoon, Lee, Juyeon, Lee, Seon Ah, Lee, Seon Ju, Choi, Ah Hyun, Kim, Jung Seo, Kim, Su Jin, Kim, Hyo Jin, Lee, Cherin, Kim, Yejin, Kim, Joohyeon, Choi, Jonghee, Jung, Byungchae, Kim, Taeho, Nam, HyeonTaek, Kim, Hyungjun, Lee, Yonghyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503894/
https://www.ncbi.nlm.nih.gov/pubmed/36145716
http://dx.doi.org/10.3390/pharmaceutics14091969

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503894/
https://www.ncbi.nlm.nih.gov/pubmed/36145716
http://dx.doi.org/10.3390/pharmaceutics14091969

Ejemplares similares